- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06345079
Cese de los análogos de la somatostatina después de la PRRT en tumores neuroendocrinos del intestino medio (STOPNET)
Un estudio aleatorizado sobre el cese de los análogos de la somatostatina después de la terapia con radionúclidos receptores de péptidos en tumores neuroendocrinos del intestino medio (STOPNET)
Neuroendocrine tumours (NETs) are slow growing cancers, which commonly present as metastatic incurable disease. Some neuroendocrine tumours, termed functional NETs, overproduce hormones which result in a variety of symptoms. However, approximately 75% of NETs are considered non-functional meaning that they do not result in hormone overproduction. The main treatment for both functional and non-functional NETs is somatostatin analogues (SSA, a type of inhibitory hormone). These drugs slow tumour growth and reduce hormone production. Over time, the majority of patients will experience tumour growth despite treatment with SSA therapy. When this occurs, the addition of Peptide Receptor Radionuclide Therapy (PRRT, a type of targeted radiotherapy) in combination with ongoing SSA therapy is given. However, it is not known if continuing SSA therapy after commencement of PRRT is beneficial or not.
The aim of this study is to estimate the outcomes of patients with grade 1 and 2 well differentiated mid, hind-gut or pancreatic neuroendocrine tumours who have progressed on SSA therapy and receive subsequent PRRT with or without concurrent SSA.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Neuroendocrine tumours commonly originate from the gut and metastasise widely including to the liver, lymph nodes and bones. Originally called "carcinoid tumours", these cancers are most commonly treated with somatostatin analogues (SSA) first line. These analogues treat carcinoid syndrome and slow tumour growth. Despite SSA therapy, progression develops over time. Upon progression, peptide receptor radionuclide therapy (PRRT) is the next standard therapeutic option. After PRRT is initiated, it is unclear if continuing SSA injections is beneficial. There are reasons to believe it might be necessary to continue SSAs, but other reasons to believe they should cease. Given that SSA injections are expensive and associated with side effects, this study aims to clarify the utility of continuing SSA injections after progression on SSA therapy and commencement of PRRT.
STOPNET aims to explore outcomes in grade 1 and 2 mid, hind gut or pancreatic neuroendocrine tumours, that have progressed on SSA therapy, are eligible to receive PRRT and in whom the SSA is either continued or ceased after PRRT is commenced.
The two primary objectives include
-
To estimate the 20-month progression free survival rate after PRRT commencement in patients who cease and who continue SSA.
-
Feasibility as measured by:
- Recruitment rate and
- Patient acceptance of ceasing and staying off SSA over the 20 month follow up period.
The study design of STOPNET is prospective, randomised, non-comparative, open label, multicentre phase II study. Patients meeting the inclusion and exclusion criteria will be randomised, prior to commencing PRRT, to either continue or cease SSA treatment. Randomisation will occur centrally in REDCap by the AGITG STOPNET study team. Randomisation will be 2:1 (the majority being randomised to cease SSA) and will be stratified by WHO tumour grade (1 V 2), sites of metastases (visceral only verse visceral and bone) and institution.
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 2
Contactos y Ubicaciones
Estudio Contacto
- Nombre: STOPNET Project Manager
- Número de teléfono: +61 1300 666 769
- Correo electrónico: gct_stopnet_mailbox@gicancer.org.au
Ubicaciones de estudio
-
-
New South Wales
-
Sydney, New South Wales, Australia, 2065
- Reclutamiento
- Royal North Shore Hospital
-
Contacto:
- Dr David Chan
- Número de teléfono: +61 (02) 8037 4100
- Correo electrónico: david.chan@sydney.edu.au
-
Contacto:
- Cindy (Xiaofang) Han
- Correo electrónico: Xiaofang.Han@health.nsw.gov.au
-
Investigador principal:
- Dr David Chan
-
Wollongong, New South Wales, Australia, 2502
- Reclutamiento
- Wollongong Hospital
-
Contacto:
- Dr Derrick Siu
- Número de teléfono: (02) 4222 5200
- Correo electrónico: howai.siu@health.nsw.gov.au
-
Contacto:
- Victoria Cosatto
- Número de teléfono: (02) 4222 5738
- Correo electrónico: Victoria.Cosatto@health.nsw.gov.au
-
Investigador principal:
- Dr Derrick Siu
-
-
Queensland
-
Brisbane, Queensland, Australia, 4006
- Reclutamiento
- Royal Brisbane and Womens Hospital
-
Contacto:
- Poppy Sharman
- Número de teléfono: +61 (07) 3647 0865
- Correo electrónico: Poppy.sharman@health.qld.gov.au
-
Contacto:
- A/Prof Matthew Burge
- Número de teléfono: +61 07 3636 8111
- Correo electrónico: Matthew.Burge@health.qld.gov.au
-
Investigador principal:
- A/Prof Matthew Burge
-
Cairns, Queensland, Australia, 4870
- Reclutamiento
- Cairns Hospital
-
Contacto:
- A/Prof Matthew Burge
- Número de teléfono: +61 (07) 4226 0000
- Correo electrónico: Matthew.Burge@health.qld.gov.au
-
Toowoomba, Queensland, Australia, 4350
- Reclutamiento
- Toowoomba Hospital
-
Contacto:
- A/Prof Matthew Burge
- Número de teléfono: +61 (07) 4616 6000
- Correo electrónico: Matthew.Burge@health.qld.gov.au
-
-
South Australia
-
Adelaide, South Australia, Australia, 5000
- Reclutamiento
- The Queen Elizabeth Hospital
-
Contacto:
- Prof Timothy Price
- Número de teléfono: 08 8222 6410
- Correo electrónico: Timothy.Price@sa.gov.au
-
Contacto:
- Pam Cooper
- Número de teléfono: 08 8222 6410
- Correo electrónico: pamela.cooper@sa.gov.au
-
Investigador principal:
- Prof Timothy Price
-
-
Victoria
-
Melbourne, Victoria, Australia, 3000
- Reclutamiento
- Peter MacCallum Cancer Centre
-
Contacto:
- Dr Hui-Li Wong
- Número de teléfono: +61 3 8559 5000
- Correo electrónico: HuiLi.Wong@petermac.org
-
Investigador principal:
- Dr Hui-Li Wong
-
Contacto:
- Naila Pachani
- Número de teléfono: +61 3 8559 5000
- Correo electrónico: naila.pachani@petermac.org
-
-
Western Australia
-
Kalgoorlie-Boulder, Western Australia, Australia, 6430
- Reclutamiento
- Kalgoorlie Health Campus
-
Contacto:
- Dr Piyush Grover
- Número de teléfono: +61 (08) 9080 5888
- Correo electrónico: piyush.grover@health.wa.gov.au
-
Perth, Western Australia, Australia, 6150
- Reclutamiento
- Fiona Stanley Hospital
-
Contacto:
- Dr Piyush Grover
- Número de teléfono: +61 08 6152 6530
- Correo electrónico: piyush.grover@health.wa.gov.au
-
Contacto:
- Anna Cannon
- Número de teléfono: +61 08 6152 6719
- Correo electrónico: anna.cannon@health.wa.gov.au
-
Investigador principal:
- Dr Piyush Grover
-
-
-
-
Alberta
-
Edmonton, Alberta, Canadá, T6G 1Z2
- Reclutamiento
- Cross Cancer Institute
-
Contacto:
- Dr Stella Koumna
- Número de teléfono: 780-432-8771
- Correo electrónico: koumna@ualberta.ca
-
Investigador principal:
- Dr Stella Koumna
-
-
British Columbia
-
Vancouver, British Columbia, Canadá, V5Z 4E6
- Reclutamiento
- BC Cancer Agency, Vancouver Cancer Centre
-
Contacto:
- Dr Jon Loree
- Número de teléfono: 604-877-6000
- Correo electrónico: jloree@ctg.queensu.ca
-
Contacto:
- Tathiana Ruiz
- Correo electrónico: tathiana.ruiz@bccancer.bc.ca
-
Investigador principal:
- Dr Jon Loree
-
-
Ontario
-
London, Ontario, Canadá, N6A 5W9
- Reclutamiento
- London Health Sciences Centre Research Institute (LHSCRI)
-
Contacto:
- Dr David Laidley
- Número de teléfono: 519-685-8500
- Correo electrónico: David.Laidley@lhsc.on.ca
-
Contacto:
- Alisha Moynahan
- Número de teléfono: 519-685-8500
- Correo electrónico: alisha.moynahan@lhsc.on.ca
-
Investigador principal:
- Dr David Laidley
-
Ottawa, Ontario, Canadá, K1Y 1J8
- Reclutamiento
- Ottawa Hospital Research Institute
-
Contacto:
- Dr Rachel Goodwin
- Número de teléfono: 613-737-8899
- Correo electrónico: rgoodwin@toh.ca
-
Investigador principal:
- Dr Rachel Goodwin
-
Toronto, Ontario, Canadá, M5G 2M9
- Reclutamiento
- University Health Network Princess Margaret Cancer Centre
-
Contacto:
- Dr Raymond Jang
- Número de teléfono: 416-946-6508
- Correo electrónico: raymond.jang@uhn.ca
-
Investigador principal:
- Dr Raymond Jang
-
Toronto, Ontario, Canadá, TG 260
- Reclutamiento
- Odette Cancer Centre Sunnybrook Health Sciences Centre
-
Contacto:
- Dr Sten Myrehaug
- Número de teléfono: 416-480-4834
- Correo electrónico: sten.myrehaug@sunnybrook.ca
-
Investigador principal:
- Dr Sten Myrehaug
-
-
Saskatchewan
-
Regina, Saskatchewan, Canadá, S4T 7T1
- Reclutamiento
- Allan Blair Cancer Centre
-
Contacto:
- Dr Mussawar Iqbal
- Número de teléfono: 306-766-2213
- Correo electrónico: mussawar.iqbal@saskcancer.ca
-
Investigador principal:
- Dr Mussawar Iqbal
-
Saskatoon, Saskatchewan, Canadá, S7N 4H
- Reclutamiento
- Saskatoon Cancer Centre
-
Contacto:
- Dr Mita Manna
- Número de teléfono: 306-655-2640
- Correo electrónico: mita.manna@saskcancer.ca
-
Investigador principal:
- Dr Mita Manna
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
-
Adults over 18 years of age with well or moderately differentiated mid or hindgut neuroendocrine tumour, or pancreatic neuroendocrine tumour; metastatic and inoperable, demonstrating progression despite SSA treatment of sufficient disease magnitude to warrant PRRT as determined by the treating clinician and/or the NET Multidisciplinary Team (MDT). See section 4.1 regarding the recording of the reason(s).
-
Must have measurable disease on triphasic CT/MRI as per RECIST 1.1.
-
Ki67 ≤20% AND mitotic count ≤20 per HPF (i.e., WHO grade 1 or 2).
• Note: Participants are eligible if only a single proliferation index has been performed due to local institutional practice, provided that the results are consistent with WHO grade 1 or 2 NET. However, if the results for both Ki67 and mitotic count are available, both results will need to be reported and are subject to eligibility assessment.
-
Non-functioning NET: SSA treatment will have been commenced for control of tumour growth and not for carcinoid or other hormone overproduction syndrome, as judged by the clinician and/or NET MDT. Non-functioning NET is judged by the treating clinical team based on patient symptomatology.
In addition, for this study, non-functioning tumour is defined as:
-
Never had escalation of the SSA treatment dose to control carcinoid or other hormone-related symptoms.
-
Never required short acting SSA treatment to control carcinoid or other hormone-related symptoms.
-
For mid and hind gut (GI cohort) patients:
- 24-hour urine 5-hydroxyindoleacetic acid (5HIAA) <3x upper limit of normal.
- No significant carcinoid induced valvular heart disease. I.e. Echocardiogram to be within 12 weeks of study randomisation, and deemed safe to proceed with PRRT by the treating team.
-
Note: routine measurement of gastrin, insulin, C-peptide levels, glucagon etc. is not required unless clinically indicated.
-
-
Patient has been receiving growth-controlling doses of SSA for at least 12 weeks prior to study enrolment, for example a minimum of 30mg Octreotide or 120mg Lanreotide monthly. However, other SSA formulations used at growth-controlling doses are also eligible.
-
Uptake on SSTR PET scan demonstrating somatostatin receptor expression that is suitable for PRRT as judged by the clinical team. FDG PET scans are to be done at the judgement of the treating team and are not required for enrolment into this study.
-
PRRT is deemed the most appropriate next treatment step (i.e., patient is inoperable, and liver directed therapies are not preferred).
-
ECOG performance status 0-2.
-
Written informed consent. Patients must be willing to either cease or continue SSA, depending on which study arm they are randomised to. Patients must be willing to comply with all other study requirements.
-
Adequate renal, hepatic and haematologic function as judged by the treating team.
-
Life expectancy of at least 12 months.
Exclusion Criteria:
- This study is for pancreatic, mid-gut and hind-gut NET only. Gastric and lung NETs are excluded.
- Any patient on an SSA dose lower than the standard growth-control dose. Patients must have been on an SSA equivalent to Octreotide 30mg or Lanreotide 120mg for at least 3 months prior to study enrolment.
- Prior chemotherapy or targeted therapy (e.g., everolimus). Patients who have received prior local therapy, including external beam radiotherapy and liver directed therapy prior to or during SSA therapy are eligible.
- Any contraindication to PRRT, as per local institutional practice.
- Pregnancy. For female patients of childbearing potential and male patients with a female partner who is of childbearing potential, contraception and counselling is required.
- Prior PRRT. Patients being considered for re-treatment with PRRT are not eligible.
- Uncontrolled central nervous system metastases. Patients must have completed any surgery or radiation at least 4 weeks prior to enrolment and must be off corticosteroids for at least 2 weeks.
- Any patient, in the opinion of the investigator, who will not comply with study assessments and follow up visits. These might include any social, psychological, or geographical concerns, including alcohol/drug abuse.
- Any poorly controlled concurrent medical illness that may prevent the patient from complying with study assessments and follow up. This is to be judged by the treating team.
- Any concurrent or prior malignancy that, in the opinion of the treating team, may interfere with study assessments and endpoints.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Comparador activo: Continue SSA
Patients randomised to continue SSA will receive SSA injection 28 days (+/- 7 days) prior to the first PRRT cycle, and continue to receive SSA every 28 days (+/- 7 days) during and after the completion of PRRT. |
Patients randomised to continue SSA will receive SSA injection 28 days (+/- 7 days) prior to the first PRRT cycle, and continue to receive SSA every 28 days (+/- 7 days) during and after the completion of PRRT.
Otros nombres:
|
|
Experimental: Cease SSA
Patients randomised to cease SSA will receive SSA injection ≥28 days prior to their first cycle of PRRT. Patients will not receive any further long acting SSA injections after this time. |
Patients randomised to cease SSA will receive their last SSA injection ≥28 days prior to their first cycle of PRRT and will remain off SSA for the duration of the study. If there is concern from the treating team that a patient may experience a carcinoid flare after PRRT, then short acting octreotide is allowed to be used to control any symptoms.
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
20-month progression free survival rate after PRRT
Periodo de tiempo: 20 months
|
Estimate the 20-month progression free survival rate after PRRT in patients who cease and who continue SSA. |
20 months
|
|
Assess the barriers which would impede the feasibility of a subsequent phase 3 trial
Periodo de tiempo: 20 months
|
|
20 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Measure Quality of life using the European Organisation For Research And Treatment Of Cancer (EORTC) Core Quality of Life questionnaire (QLQ-C30) scales
Periodo de tiempo: 20 months
|
Responses to the QLQ-C30 scale from 0-100 using EORTC guidelines, with higher scores reflecting better level of functioning. |
20 months
|
|
Measure Quality of life using the EORTC QLQ-GINET21 scales
Periodo de tiempo: 20 months
|
Responses to the QLQ-GINET21 scale from 0-100 using EORTC guidelines, with higher scores reflecting more severe symptoms. |
20 months
|
|
Cost-effectiveness of SSA therapy cessation
Periodo de tiempo: The MBS/PBS data will be obtained for the period six months prior to study entry, and until the end of 2 years follow-up post PRRT for patients who have provided consent.
|
Access to Medicare and PBS data to asses use of other healthcare providers, diagnostic tests and imaging services funded via public health care systems and use of pharmaceutical services respectively. |
The MBS/PBS data will be obtained for the period six months prior to study entry, and until the end of 2 years follow-up post PRRT for patients who have provided consent.
|
|
Psycho-oncological impacts of SSA therapy cessation: Decision Regret
Periodo de tiempo: 20 months
|
Psycho-oncological impacts of SSA therapy cessation using the self-reported measures of Decision Regret Scale from 1 - 5 (1-Strongly Agree, 2-Agree, 3-Neither Agree Nor Disagree, 4-Disagree, 5-Strongly Disagree) |
20 months
|
|
Psycho-oncological impacts of SSA therapy cessation: Fear of Cancer Progression
Periodo de tiempo: 20 months
|
Psycho-oncological impacts of SSA therapy cessation using the self-reported measures of the Fear of Cancer Progression Scale from 1 - 5 (1-Never, 2-Seldom, 3-Sometimes, 4-Often, 5-Very often) |
20 months
|
|
Psycho-oncological impacts of SSA therapy cessation: Decisional Conflict
Periodo de tiempo: 20 months
|
Psycho-oncological impacts of SSA therapy cessation using the self-reported measures of the Decisional Conflict Scale from 0 - 4 (0-Strongly Agree, 1-Agree, 2-Neither Agree Nor Disagree, 3-Disagree, 4-Strongly Disagree) |
20 months
|
|
Time to commencement of subsequent therapy
Periodo de tiempo: 20 months
|
Time to commencement of subsequent therapy (e.g re-challenge with PRRT, liver directed therapies, chemotherapy, targeted therapies) |
20 months
|
|
Overall survival
Periodo de tiempo: 20 months
|
Estimate the 20-month overall survival rate in patients who cease and who continue SSA. |
20 months
|
|
Rates of SSA being recommenced over time
Periodo de tiempo: 20 months
|
Cumulative percentage of SSA recommencement over time. |
20 months
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Exploratory analyses
Periodo de tiempo: 20 months
|
Exploratory analyses including, but not limited to: Define and validate NET tissue and circulating biomarkers with a particular focus on miRNA. |
20 months
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- AG0219NET
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .